Open an account

GH Research

GHRS · NASDAQ

$19.17+$0.885 (+4.84%)TodayMarket closed ·
Prev close $18.28

About GHRS

GH Research Plc is a holding company, which engages in the provision of biopharmaceutical products and services. The firm is engaged in offering treatment for psychiatric and neurological disorders. The firm's pipeline includes GH001, GH002 and GH003. The firm focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.

Employees
73
Headquarters
DUBLIN, Dublin
Listed
Jun 25, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
ghres.com

GHRS key statistics

Market cap
1.25B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
311.05K
Volume
276.99K
Open price
$18.30
High today
$19.43
Low today
$18.11
52 Week high
$31.44
52 Week low
$12.04

GH Research (GHRS) at a glance

As of Oct 20, 2026, GH Research (GHRS) shares are priced at $19.17, giving the company a market cap of 1.25B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $18.11 and $19.43. The current price is 5.8% above the day's low and 1.4% below its high.

Volume so far is 276.99K shares, in line with the average of 311.05K shares a day.

Over the past year GH Research has ranged from $12.04 to $31.44, and now sits 37% of the way up that range.

GH Research met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.23 per share against an estimate of -$0.3091.

The average analyst price target is $42.53, 121.9% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 8 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 12 analystsAvg $42.53
Low
$31.31
Now
$19.17
High
$68.25

GHRS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 24.6% on average.

  1. Q3 FY24: reported -$0.23 per share against an estimate of -$0.2565
  2. Q4 FY24: reported -$0.17 per share against an estimate of -$0.2482
  3. Q1 FY25: reported -$0.19 per share against an estimate of -$0.3978
  4. Q2 FY25: reported -$0.15 per share against an estimate of -$0.218
  5. Q3 FY25: reported -$0.23 per share against an estimate of -$0.2414
  6. Q4 FY25: reported -$0.23 per share against an estimate of -$0.2754
  7. Q1 FY26: reported -$0.31 per share against an estimate of -$0.2823
  8. Q2 FY26: reported -$0.23 per share against an estimate of -$0.3091

GHRS news

  • Press releasePRNewswire

    A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening

  • Press releasePRNewswire

    Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time

  • Vandana Singh

    Why Is GH Research Stock Trading Higher on Thursday?

  • Press releaseGlobe Newswire

    Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

  • Press releasePRNewswire

    A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

  • Namrata Sen

    Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On?

  • Press releasePRNewswire

    CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

  • Press releasePRNewswire

    Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Similar companies

Companies in the same industry as GH Research

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.